189 related articles for article (PubMed ID: 33247676)
21. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
22. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract][Full Text] [Related]
23. A bioinformatics analysis of the clinicopathological and prognostic significance of
Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of the novel omicron receptor AXL in cancers.
Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
[TBL] [Abstract][Full Text] [Related]
25. Genome and transcriptome profiling of
Lan R; Jin B; Liu YZ; Zhang K; Niu T; You Z
Am J Clin Exp Urol; 2020; 8(4):116-128. PubMed ID: 32929407
[TBL] [Abstract][Full Text] [Related]
26. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.
Khan R; Pari B; Puszynski K
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205
[TBL] [Abstract][Full Text] [Related]
28. Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.
De Faveri LE; Hurst CD; Platt FM; Taylor CF; Roulson JA; Sanchez-Carbayo M; Knowles MA; Chapman EJ
Br J Cancer; 2013 Apr; 108(6):1368-77. PubMed ID: 23549060
[TBL] [Abstract][Full Text] [Related]
29. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
30. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of TC2N is associated with poor prognosis in gastric cancer.
Xu J; Ou X; Li J; Cai Q; Sun K; Ye J; Peng J
J Cancer; 2021; 12(3):807-817. PubMed ID: 33403038
[No Abstract] [Full Text] [Related]
32. TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers.
Li H; Fang H; Chang L; Qiu S; Ren X; Cao L; Bian J; Wang Z; Guo Y; Lv J; Sun Z; Wang T; Li B
Front Immunol; 2021; 12():764749. PubMed ID: 34925334
[TBL] [Abstract][Full Text] [Related]
33. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
34. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
Saglam O; Tang Z; Tang G; Medeiros LJ; Toruner GA
PLoS One; 2020; 15(9):e0238477. PubMed ID: 32877461
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Liu B; Fu X; Du Y; Feng Z; Chen R; Liu X; Yu F; Zhou G; Ba Y
Carcinogenesis; 2023 Aug; 44(6):525-534. PubMed ID: 37335542
[TBL] [Abstract][Full Text] [Related]
37. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract][Full Text] [Related]
38. Multi-Omics Analysis of the Prognostic and Immunological Role of Runt-Related Transcription Factor 3 in Pan-Cancer.
Zhou Q; Ding DD; Lu M; Zuo MZ
Crit Rev Eukaryot Gene Expr; 2023; 33(4):63-83. PubMed ID: 37183947
[TBL] [Abstract][Full Text] [Related]
39. The androgen receptor expression and association with patient's survival in different cancers.
Hu C; Fang D; Xu H; Wang Q; Xia H
Genomics; 2020 Mar; 112(2):1926-1940. PubMed ID: 31759122
[TBL] [Abstract][Full Text] [Related]
40. CASC5 is a potential tumour driving gene in lung adenocarcinoma.
Cui Y; Zhang C; Ma S; Guo W; Cao W; Guan F
Cell Biochem Funct; 2020 Aug; 38(6):733-742. PubMed ID: 32283571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
